{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=15",
    "query": {
      "intervention": "Monoclonal antibody - Dose Escalation",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 886,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T11:43:57.776Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00887926",
      "title": "Study of IMC-EB10 in Participant With Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "IMC-EB10",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2009-06",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00887926"
    },
    {
      "nct_id": "NCT01629758",
      "title": "Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms by Site"
      ],
      "interventions": [
        {
          "name": "Denenicokin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-06",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01629758"
    },
    {
      "nct_id": "NCT04311632",
      "title": "A Dose Escalation Study in de Novo Renal Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "TCD601",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tacrolimus (TAC)",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids (CS)",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ITB-Med LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-05-26",
      "completion_date": "2023-10-03",
      "has_results": true,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Kansas City, Kansas • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Livingston",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04311632"
    },
    {
      "nct_id": "NCT03181009",
      "title": "Multi OIT to Test Immune Markers After Minimum Maintenance Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Food Flour Allergens",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew Long, PharmD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-07-31",
      "completion_date": "2019-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Mountain View, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181009"
    },
    {
      "nct_id": "NCT05200364",
      "title": "A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "Ovary Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "STRO-002",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2022-03-22",
      "completion_date": "2025-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 6,
      "location_summary": "Tampa, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05200364"
    },
    {
      "nct_id": "NCT02423343",
      "title": "A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Non-Small Cell Lung Cancer Recurrent",
        "Hepatocellular Carcinoma Recurrent"
      ],
      "interventions": [
        {
          "name": "Galunisertib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2015-01-01",
      "completion_date": "2020-07-08",
      "has_results": true,
      "last_update_posted_date": "2021-09-09",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02423343"
    },
    {
      "nct_id": "NCT06819735",
      "title": "Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "DT-7012",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Domain Therapeutics Australia Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2025-06-25",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06819735"
    },
    {
      "nct_id": "NCT00405405",
      "title": "Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Parotid Gland Cancer",
        "Thyroid Gland Cancer",
        "Melanoma",
        "Stage IV Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2006-12",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00405405"
    },
    {
      "nct_id": "NCT04104672",
      "title": "A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "AB680",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2019-11-06",
      "completion_date": "2026-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 9,
      "location_summary": "Santa Monica, California • St Louis, Missouri • New York, New York + 5 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04104672"
    },
    {
      "nct_id": "NCT04084951",
      "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "SQZ-PBMC-HPV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "SQZ Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-01-28",
      "completion_date": "2023-02-09",
      "has_results": false,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-10-14T11:43:57.776Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04084951"
    }
  ]
}